Correlation Between Novo Nordisk and Genmab AS

Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and Genmab AS at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and Genmab AS into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Novo Nordisk AS and Genmab AS, you can compare the effects of market volatilities on Novo Nordisk and Genmab AS and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Genmab AS. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Genmab AS.

Diversification Opportunities for Novo Nordisk and Genmab AS

0.93

Correlation Coefficient

Novo Nordisk  Genmab AS

Almost no diversification

The 3 months correlation between Novo and Genmab is 0.93. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Genmab AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genmab AS and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Genmab AS. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genmab AS has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and Genmab AS go up and down completely randomly.

Pair Corralation between Novo Nordisk and Genmab AS

Assuming the 90 days trading horizon Novo Nordisk AS is expected to generate 1.29 times more return on investment than Genmab AS. However, Novo Nordisk is 1.29 times more volatile than Genmab AS. It trades about -0.15 of its potential returns per unit of risk. Genmab AS is currently generating about -0.2 per unit of risk. If you would invest  92,910  in Novo Nordisk AS on September 2, 2024 and sell it today you would lose (17,180) from holding Novo Nordisk AS or give up 18.49% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

Novo Nordisk AS  vs.  Genmab AS

Novo Nordisk AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Genmab AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Genmab AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Novo Nordisk and Genmab AS

The main advantage of trading using opposite Novo Nordisk and Genmab AS positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, Genmab AS can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genmab AS will offset losses from the drop in Genmab AS's long position.

The idea behind Novo Nordisk AS and Genmab AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.